Statistical Significance and P-Values in Clinical Trials

Why P-Values Decide Outcomes

When a Phase 3 trial reads out, the headline often hinges on a single number: the p-value on the primary endpoint. Understanding what that number means — and what it does not — separates investors who can read a readout from those who react to spin.

A p-value answers one narrow question: if the drug truly had no effect, how likely would we be to see a result at least this extreme by chance alone? A p-value of 0.03 means there's roughly a 3% probability of seeing this result if the drug did nothing.

The 0.05 Threshold

By convention, a result is "statistically significant" if the p-value is below 0.05. This threshold is what trials are powered around: the FDA generally expects pre-specified primary endpoints to clear it.

A few critical clarifications:

• p < 0.05 is a yes/no gate, not a quality score. A drug that hits p = 0.049 met its endpoint; one at p = 0.051 did not. The biology may be similar, but the regulatory verdict differs.
• A "trend toward significance" (e.g., p = 0.08) is a miss. Companies sometimes describe near-misses this way. In confirmatory testing, close doesn't count.
• Two positive trials are often expected. For many indications the FDA wants substantial evidence — frequently two adequate and well-controlled studies, or one very robust study — not a single borderline result.

Statistical Significance ≠ Clinical Significance

This is the most important distinction and the one investors most often miss. A result can be statistically significant yet clinically trivial. If a trial is large enough, even a tiny difference can clear p < 0.05.

So always ask two questions in sequence:

1. Is it statistically significant? Did the primary endpoint hit p < 0.05?
2. Is the effect size clinically meaningful? Does the magnitude of benefit actually matter to patients and prescribers — enough to win a label and adoption?

A statistically significant but clinically marginal result can still struggle at an advisory committee or fail to gain commercial traction even after approval.

Confidence Intervals: The Underrated Number

Alongside the p-value, look at the confidence interval around the effect size. It tells you the plausible range of the true effect. A significant result with a wide confidence interval that nearly touches "no effect" is shakier than one with a tight interval comfortably away from zero. The confidence interval conveys precision in a way the p-value alone does not.

Common Ways to Be Fooled

• Subgroup mining. A failed overall trial with a "significant" subgroup is usually a false positive unless that subgroup was pre-specified and statistically protected.
• Multiple endpoints without correction. Testing many outcomes inflates the chance of a spurious "win." Pre-specified hierarchical testing guards against this.
• Post-hoc analyses. Analyses dreamed up after seeing the data are hypothesis-generating, not confirmatory.

Applying It

Before a Phase 3 readout, know the trial's statistical plan: the primary endpoint, the powering assumptions, and how many trials the FDA expects. After the readout, confirm the primary hit p < 0.05, check the effect size and confidence interval, and be skeptical of subgroup or secondary-endpoint spin when the primary missed.

A clean, pre-specified, statistically significant and clinically meaningful result is what carries a program toward its FDA decision. To follow upcoming readouts and the companies behind them, use the catalyst calendar and the relevant company page.